Citadel Advisors
NMRA icon

Citadel Advisors’s Neumora Therapeutics NMRA Stock Holding History

Citadel Advisors’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$256K Buy
150,600
+109,200
+264% +$208K ﹤0.01% 11484
2026
Q1 		$80.7K Buy
41,400
+6,600
+19% +$17.1K ﹤0.01% 12167
2025
Q4 		$62.3K Sell
34,800
-66,500
-66% -$146K ﹤0.01% 11927
2025
Q3 		$184K Buy
101,300
+25,800
+34% +$41.7K ﹤0.01% 11342
2025
Q2 		$55.4K Sell
75,500
-51,600
-41% -$39.1K ﹤0.01% 11720
2025
Q1 		$127K Buy
127,100
+1,900
+2% +$3.25K ﹤0.01% 11125
2024
Q4 		$1.33M Buy
125,200
+121,300
+3,110% +$1.45M ﹤0.01% 6462
2024
Q3 		$51.5K Buy
3,900
+800
+26% +$9.33K ﹤0.01% 11873
2024
Q2 		$30.5K Sell
3,100
-1,400
-31% -$14.5K ﹤0.01% 12257
2024
Q1 		$61.9K Sell
4,500
-900
-17% -$14.6K ﹤0.01% 11963
2023
Q4 		$92.1K Buy
+5,400
New +$66.3K ﹤0.01% 11039

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors's NMRA Position: Q2 2026 in Review

Citadel Advisors increased its Neumora Therapeutics (NMRA) stake by 141% in Q2 2026, buying an estimated $924K and bringing the position to 828,933 shares worth $1.41M. The position accounts for ﹤0.01% of the portfolio, ranked #7371.

Citadel Advisors first reported a position in NMRA in Q3 2023 and has held it in 10 quarters since. The position peaked at $30.3M in Q4 2023. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Citadel Advisors held 828,933 shares of Neumora Therapeutics worth $1.41M as of Q2 2026.
  • Citadel Advisors bought 485,347 Neumora Therapeutics shares in Q2 2026, an estimated $924K.
  • Neumora Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7371 holding.
  • Citadel Advisors first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 10 quarters since.
  • Citadel Advisors's Neumora Therapeutics position peaked at $30.3M in Q4 2023.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.